COST-UTILITY ASSESSMENT OF SIROLIMUS VERSUS TACROLIMUS FOR PRIMARY PREVENTION OF GRAFT REJECTION IN RENAL TRANSPLANT RECIPIENTS IN MEXICO

被引：1

作者：

Rely, K. ^{[1
]}

Alexandre, P. K. ^{[2
]}

Garcia-Garcia, E. G. ^{[3
]}

Mucino-Ortega, E. ^{[3
]}

Salinas-escudero, G. ^{[4
]}

Galindo-Suarez, R. M. ^{[3
]}

机构：

[1] CEAHealthTech, Mexico City, DF, Mexico

[2] Johns Hopkins Univ, Baltimore, MD USA

[3] Pfizer SA CV, Mexico City, DF, Mexico

[4] Hosp Infantil Mexico Dr Federico Gomez, Secretaria Salud, Mexico City, DF, Mexico

来源：

VALUE IN HEALTH | 2012年 / 15卷 / 04期

关键词：

D O I：

10.1016/j.jval.2012.03.840

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A156 / A156

页数：1

共 44 条

[1] Sirolimus/tacrolimus combination is associated with low acute rejection and preservation of longterm graft function in pediatric renal transplant recipients.
El-Sabrout, Rafik A.
Butt, Khalid M. H.
Weiss, Robert
[J]. PEDIATRIC TRANSPLANTATION, 2007, 11 : 58 - 58
[2] Sirolimus Versus Tacrolimus in Kidney Transplant Recipients Receiving Mycophenolate Mofetil and Steroids: Focus on Acute Rejection, Patient and Graft Survival
Yang, Aifang
Wang, Bin
[J]. AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (02) : 98 - 104
[3] Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients
Ponticelli, C
[J]. TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 1031 - 1032
[4] Evaluation of the cost utility of sirolimus versus tacrolimus for immunosuppression for renal transplantation in the United Kingdom
Currie, CJ
Dixon, S
Conway, P
McEwan, P
[J]. VALUE IN HEALTH, 2004, 7 (06) : 800 - 800
[5] Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients
El-Sabrout, R
Weiss, R
Butt, F
Delaney, V
Qadir, M
Hanson, P
Butt, K
[J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1942 - 1943
[6] Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
Kreis, H
Cisterne, JM
Land, W
Wramner, L
Squifflet, JP
Abramowicz, D
Campistol, JM
Morales, JM
Grinyo, JM
Mourad, G
Berthoux, FC
Brattström, C
Lebranchu, Y
Vialtel, P
[J]. TRANSPLANTATION, 2000, 69 (07) : 1252 - 1260
[7] The safety and efficacy of sirolimus/cyclosporine for the prevention of acute rejection in primary renal allograft recipients.
Mathew, TH
[J]. TRANSPLANTATION, 2000, 69 (08) : S360 - S360
[8] A COST-UTILITY ANALYSIS OF PROLONGED-RELEASE TACROLIMUS RELATIVE TO IMMEDIATE-RELEASE TACROLIMUS AND CICLOSPORIN IN LIVER TRANSPLANT RECIPIENTS IN THE UK
Muduma, G.
Odeyemi, I. A.
Pollock, R. F.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A628 - A629
[9] A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK
Muduma, Gorden
Odeyemi, Isaac
Pollock, Richard F.
[J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 995 - 1002
[10] Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients - A single center experience
El-Sabrout, R
Delaney, V
Qadir, M
Butt, F
Hanson, P
Butt, KMH
[J]. TRANSPLANTATION PROCEEDINGS, 2003, 35 (3A) : 89S - 94S

← 1 2 3 4 5 →